INMBHealthcare · BiotechnologyThe 3 Wall Street analysts covering INmune Bio, Inc. hold a median 12-month price target of $8 — +323.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 10 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores INmune Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INMB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +323.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Mar 2026 | LUCID CAPITAL MARKETS | Upgrade | Buy | $2.00 → $9.00 |
| 2 July 2025 | Maxim Group | Maintains | Buy | — |
| 1 July 2025 | BTIG | Downgrade | Neutral | — |
| 1 July 2025 | Scotiabank | Downgrade | Sector Underperform | — |
| 13 Feb 2025 | Maxim Group | Maintains | Buy | — |
| 11 Feb 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 21 Oct 2024 | Alliance Global Partners | Initiates | Buy | $20 |
| 27 Sept 2024 | Raymond James | Initiates | Outperform | $18 |
| 22 Aug 2024 | Scotiabank | Initiates | Sector Outperform | $22 |
| 1 June 2023 | Baird | Initiates | Outperform | — |
| 24 May 2022 | B. Riley Securities | Downgrade | Neutral | — |
| 24 May 2022 | BTIG | Maintains | Buy | — |
| 24 Jan 2022 | B. Riley Securities | Maintains | Buy | — |
| 21 Apr 2021 | B. Riley FBR | Initiates | Buy | — |
| 21 Apr 2021 | B. Riley Securities | Initiates | Buy | — |
| 25 Nov 2020 | BTIG | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 25 Nov 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INMB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, INmune Bio, Inc. returned −4.5% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 1% of US stocks
Cheaper than 36% of US stocks
Cheaper than 74% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
INmune Bio, Inc. has a market value of $52.5M and an enterprise value of $34.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$18.4M.
Free cash flow in the twelve months to 30 June 2026: −$15.7M.
Trailing P/E: −1.0×; forward P/E: −4.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
INmune Bio, Inc. employs 21 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own INmune Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
INmune Bio announced that it will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 at The Hard Rock Hotel NYC.
Why it matters — INMB watchers may note the company’s participation in an upcoming industry summit.
INmune Bio announced the appointment of a Sanofi rare-disease executive and a biopharma business development leader to its board. The appointments are intended to strengthen the company's rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel advances toward potential commercialization.
Why it matters — The new board members bring expertise in rare-disease commercialization and business development, which could support INmune Bio's preparations as Ebstrocel moves closer to potential commercialization.
INmune Bio announced it will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET).
Why it matters — INMB watchers would care because the conference presentation offers an opportunity for the company to communicate its progress to the investment community.
The article discusses INmune Bio's candidate Ebstrocel for recessive dystrophic epidermolysis bullosa (RDEB), noting potential UK regulatory alignment and positioning for UK, EU, and US regulatory filings by early 2027. It highlights Ebstrocel's systemic itch reduction as a differentiator from competitors.
Why it matters — INMB watchers would care because the reported regulatory alignment and anticipated filing milestones for Ebstrocel could be a key catalyst for the company's valuation.
INmune Bio has submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB). These filings support a planned European marketing authorization application in Q1 2027.
Why it matters — A watcher of INMB would care because advancing Ebstrocel™ toward European marketing authorization could, if orphan designation is granted and maintained, bring regulatory incentives including 10 years of market exclusivity.
The 3 Wall Street analysts covering INmune Bio, Inc. have a median 12-month price target of $8, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering INmune Bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INmune Bio, Inc. 55 out of 100 across roughly 4,600 US stocks as at 10 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Oct 2026, INmune Bio, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +323.3% from the last close, and Ticker Nerd's factor model ranks INmune Bio, Inc. 55 out of 100 as at 10 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering INmune Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.
INmune Bio, Inc. returned -4.5% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "INmune Bio to Attend the 2026 Maxim Growth Summit". INmune Bio announced that it will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 at The Hard Rock Hotel NYC.
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.
CEO Mr. David J. Moss M.B.A. · 21 employees · United States · https://www.inmunebio.com
